Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells target Stomach-Lining tumors in colorectal cancer

NCT ID NCT07247396

First seen Dec 02, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This early-stage trial is testing a new treatment for people with advanced colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases). Participants first have surgery to remove as much tumor as possible, then receive an infusion of their own immune cells that have been genetically modified to recognize and attack cancer cells carrying a protein called CEA. The study aims to find a safe dose and check for side effects in 12 adults who have already tried standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERITONEAL METASTASES FROM COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310017, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.